Obesity drugs shed niche tag, set to gain more weight in India pharma
Obesity drugs are rapidly moving from the margins of lifestyle care to the centre of India’s pharmaceutical growth story as rising lifestyle diseases, new blockbuster launches and the looming entry of low-cost generics reshape the market. With global consultants McKinsey ranking obesity therapies alongside AI, electric vehicles and robotics as trillion-dollar opportunities by 2040, India…
